AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00298272
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo on Day 1 and Day 15
Trial: NCT00298272
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants must have been treated with MTX ≥15 mg per week and ≤25 mg per week (dose may have been as low as 10 mg if unable to tolerate higher dose) for at least 12 weeks immediately prior to Day 1, at a stable dose for at least 4 weeks and was continued for the study duration.
Trial: NCT02503124
Drug: Treatment as usual - medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Since all patients are admitted due to a severe mental illness, they will receive medication according to indication. Most patients have already tried more than one antidepressant at the time of admission. In cases of severe anxiety, anxiolytics are prescribed but this is kept to a minimum.
Trial: NCT02527746
Drug: EC regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 100 mg/m\^2 (in vein) and Cyclophosphamide 600 mg/m\^2 (in vein) on Day 1 of each cycle for 4 cycles.
Trial: NCT00858455
Drug: GSK1349572 and MaaloxAdvanced Maximum Strength
RxNorm normalized name: Ivarest Maximum Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of GSK1349572 co-administered with a single dose of 20 mL of Maalox Advanced Maximum Strength
Trial: NCT00858455
Drug: GSK1349572 and Maalox Advanced Maximum Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of GSK1349572 administered 2 hours prior to administration of a single dose of 20 mL of Maalox Advanced Maximum Strength
Trial: NCT00858455
Drug: GSK1349572 and One A Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of GSK1349572 50 mg co-administered with a single dose of a One A Day Maximum multivitamin
Trial: NCT00858455
Drug: GSK1349572
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of GSK1349572
Trial: NCT00388726
Drug: Physician's Choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of the Physician's Choice defined as any single agent chemotherapy, hormonal treatment or biological therapy approved for the treatment of cancer; or palliative treatment or radiotherapy, administered according to local practice, if applicable.
Trial: NCT04849468
Drug: Declofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: evaluating the preemptive effect of intramuscular declofenac on postoperative analgesia in patients undergoing perianal surgeries under saddle block
Trial: NCT00833495
Drug: Prednisolone Acetate 0.12% (Pred Mild®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and thermal burns). Instill one to two drops into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased if necessary.
Trial: NCT00833495
Drug: FOV1101-00
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This investigational drug is a low dose cyclosporine (also known as cyclosporine A; CsA) formulation for topical ocular administration. FOV1101-00 is presented as a solution for topical ophthalmic administration in two strengths, concentration 1 or concentration 2 w/v cyclosporine in citrate buffered aqueous vehicle. Application is intended as four times per day.
Trial: NCT00833495
Drug: Prednisolone Acetate 1% (Pred Forte®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRED FORTE® is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. Instill one to two drops into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased if necessary. Care should be taken not to discontinue therapy prematurely.
Trial: NCT00833495
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The vehicle is an eye drop that contains only the inactive ingredients of FOV1101-00.
Trial: NCT01616238
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment for all pathways consists of Induction, Intensification (where applicable), Consolidation and Maintenance therapy during which combination chemotherapy is given for up to 2.5 years.
Trial: NCT02057133
Drug: LY2835219
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT02057133
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy administered orally.
Trial: NCT03213002
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine at 1500 mg/m2
Trial: NCT05919732
Drug: Bupivacaine, Dexmedetomidine, Caffeine, Tylenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine .3% + 1: 200,000 epinephrine (dose 3mg/kg). Dexmedetomidine 0.5mcg/kg, Caffeine 15mg/kg, rectal Tylenol 30mg/kg
Trial: NCT01011751
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate, medroxyprogesterone acetate or venlafaxine placebo-matching capsule.
Trial: NCT00439712
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 placebo tablet OD in the morning for 29+/-4 days
Trial: NCT01513720
Drug: Lamictal®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamictal® 200 mg Tablets
Trial: NCT01135329
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/kg IV daily on Day +3 and Day +4.
Trial: NCT00839800
Drug: Symbicort Turbuhaler
RxNorm normalized name: Symbicort Turbuhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160/4.5 µg
Trial: NCT00474071
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See Detailed Description.
Trial: NCT03448419
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT01698892
Drug: I.V Sedation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the I.V. sedation group
Trial: NCT01698892
Drug: sublingual sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the sublingual sedation group
Trial: NCT03058562
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT02982681
Drug: Bioactive Glass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control site were packed with the bioactive glass graft alone
Trial: NCT02604992
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronabinol oral solution, under fed conditions
Trial: NCT02604992
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronabinol oral capsule, under fed conditions
Trial: NCT05919732
Drug: Propofol, rocuronium, caffeine, Tylenol, bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propofol 3mg/kg and rocuronium 0.6mg/kg. Caffeine 15mg/kg and rectal Tylenol 30mg/kg.~single shot caudal with bupivacaine 0.25% + 1:200,000 epinephrine (total dose 2.5mg/kg)
Trial: NCT00703690
Drug: MK0767
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK0767 2.5, 5, and 10 mg/day supplied as tablets
Trial: NCT01588158
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg
Trial: NCT02914613
Drug: SF0166 Topical Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00018564
Drug: treatments for essential tremor
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04349228
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of Hydroxychloroquine (HCQ) without any active substance
Trial: NCT03378674
Drug: Remifentanil Injectable Product
RxNorm normalized name: remifentanil Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remifentanil: 0,15 mcg/kg/min
Trial: NCT00740792
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo one spray per nostril BID
Trial: NCT03293992
Drug: 0.01% RO7058584
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily morning administration for 7 days
Trial: NCT03293992
Drug: 0.1% RO7058584
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily morning administration for 7 days
Trial: NCT03293992
Drug: 1% RO7058584
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily morning administration for 7 days
Trial: NCT03293992
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily morning administration for 7 days
Trial: NCT01709682
Drug: Anti-Arrhythmia Agents (propafenone, flecainide, and/or sotalol, or amiodarone)
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propafenone, flecainide, and/or sotalol as first-line drugs in patients without structural heart disease or amiodarone as a single drug or in combination in patients with structural heart disease or in case of first-line drug failure
Trial: NCT04244084
Drug: MMH-407
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral use.
Trial: NCT04244084
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral use.
Trial: NCT01052194
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, placebo b.i.d. for 12 weeks
Trial: NCT00501410
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m\^2 by vein on day 1.
Trial: NCT03192306
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol solution
Trial: NCT02417142
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo SQ 1x/week for 24 weeks.
Trial: NCT04164732
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 orally twice daily
Trial: NCT04164732
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03755557
Drug: Budesolv
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of a nasal spray
Trial: NCT01871844
Drug: ITF2984 (500, 1000, 2000 mcg bid for 7 days)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01871844
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01160848
Drug: Area cleaned with Ethyl alcohol solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01160848
Drug: Visonac left on the skin for 24 hours in facial area one
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03221816
Drug: Tenavit®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The experimental group received one tablet of Tenavit® daily for a period of 4 months.
Trial: NCT03221816
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group received the same tablet with the organoleptic characteristics of Tenavit® for a period of 4 months.
Trial: NCT01602861
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One tablet per day (25 mg Spironolactone/placebo) for the first three months. Subsequently dosage is increased to two tablets per day (50 mg Spironolactone/placebo) for the rest of the study.~In case of hyperkaliemia (\>5,5 mmol/L) or intolerable side effects dosage will be reduced to one tablet per day (25 mg Spironolactone/placebo).
Trial: NCT01602861
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00027066
Drug: Aspirin placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325mg aspirin placebo pill
Trial: NCT02861222
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03768258
Drug: Testosterone Implant
RxNorm normalized name: Testosterone Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone implants or combination testosterone + anstrozole implants used to treat symptoms of hormone/androgen deficiency
Trial: NCT01313286
Drug: LY2608204 Reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01313286
Drug: LY2608204 Test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT03074058
Drug: Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931)
RxNorm normalized name: Fosrenol Chewable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931) 500mg, TID
Trial: NCT00979316
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution, Oral, 0 mg, Once on Day 1, approximately 14 days
Trial: NCT01278004
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule
Trial: NCT03136640
Drug: ModraDoc006/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
Trial: NCT02011633
Drug: Rosuvastatin 10mg
RxNorm normalized name: ROSUVASTATIN 10MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Co-administration of Metformin 500mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
Trial: NCT00295022
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Pharmaceutical form: Over-encapsulated tablet~* Route of administration: Oral use
Trial: NCT02744729
Drug: 99mTc-3PRGD2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients in suspicion of esophagus cancer, single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and thoracic SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.
Trial: NCT02976740
Drug: Immunological Agent
RxNorm normalized name: IMMUNOLOGICAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of human recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle. Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle.
Trial: NCT02976740
Drug: Immunological Factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymosin Alpha 1(1.6mg Biw)will be executed from the fist Week to the 12th Weeks.
Trial: NCT00154284
Drug: Steroid
RxNorm normalized name: Steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient was administered i.v. prednisone (or equivalent) pre- or intra-operatively according to center practice.
Trial: NCT02084043
Drug: Nebulization of Amikacin during NIV (RR: 15 cycles/minute)
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds. The NIV is set with an IPAP of 15 cmH2O and EPAP of 5 cmH2O. The lung model is simulated with a respiratory rate of 15 cycles/minute
Trial: NCT02084043
Drug: Nebulization of Amikacin during NIV (RR: 25 cycles/minute)
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds. The NIV is set with an IPAP of 15 cmH2O and EPAP of 5 cmH2O. The lung model is simulated with a respiratory rate of 25 cycles/minute
Trial: NCT01594736
Drug: ORSIRO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: due randomization ORSIRO will be implanted
Trial: NCT03806933
Drug: NT 201
RxNorm normalized name: Fluarix Quadrivalent 2013-2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% unpreserved Sodium Chloride (NaCl).
Trial: NCT00078767
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 weeks of Placebo pill, flexible dosage, of 50-150 mg/day, to be administered while receiving TF-CBT
Trial: NCT00596687
Drug: Regular insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sliding scale regular insulin SQ four-times daily before meals or every 6 hours if patient NPO
Trial: NCT01722825
Drug: LY2157299
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT03831113
Drug: Magnitude Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose reductions will alternate between 1mg or 2 mg weekly until the subject is no longer taking buprenorphine or is at the lowest tolerable dose.
Trial: NCT03831113
Drug: Frequency Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose reductions of 2 mg will occur alternate between once weekly to biweekly until the subject is no longer taking buprenorphine or is at the lowest tolerable dose.
Trial: NCT00172172
Drug: PTH/Calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTH(1-84) subcutaneous injection and calcium 700 mg oral
Trial: NCT00172172
Drug: PTH/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTH (1-84) injected subcutaneously and placebo provided orally
Trial: NCT00172172
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injected subcutaneously and 700 mg calcium orally
Trial: NCT01455597
Drug: WC3011 Estradiol Vaginal Cream
RxNorm normalized name: Estradiol Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WC3011 estradiol vaginal cream, 3 times a week for 40 weeks.
Trial: NCT00607074
Drug: Control group (placebo)
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every 4 weeks: Secnidazole placebo Every 12 weeks: Albendazole placebo
Trial: NCT01469130
Drug: MEK162
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEK162 in an oral formulation. It is a film-coated capsule-shape tablets (i.e. caplets).
Trial: NCT00857090
Drug: OMS201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage 1: OMS201 irrigation solution at 3X the base concentration during surgery~Stage 2: OMS201 irrigation solution up to 10X the base concentration during surgery
Trial: NCT00857090
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stages 1-2: Vehicle irrigation solution during surgery
Trial: NCT00002691
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002691
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002691
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01225016
Drug: Definity contrast agent
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid ultrasound using contrast agent
Trial: NCT01069510
Drug: Spironolactone 25mg
RxNorm normalized name: SPIRONOLACTONE 25MG TAB
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone 25 mg daily for 12 months
Trial: NCT02282813
Drug: CTAP101 Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At week 12, eligible subjects will continue to take 1-2 capsules (30 mcg each capsule) CTAP101 daily
Trial: NCT02506556
Drug: BYl719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment: BYL719 350mg orally daily Treatment will be given daily until progression, undue adverse events or withdrawal of consent.~Dose reductions (two levels) are allowed. Each cycle is 28 days
Trial: NCT00532389
Drug: LBH589
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04346667
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care plus placebo
Trial: NCT02748642
Drug: BITS7201A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BITS72014A will be administered on Day 1 in Part A and on Days 1, 28, and 57 in Part B.
Trial: NCT02748642
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to BITS72014A will be administered on Day 1 in Part A and on Days 1, 28, and 57 in Part B.
Trial: NCT03273413
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anti-inflammatory, anti-oxidative stress, and anti-proliferative therapy
Trial: NCT03273413
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive tablet
Trial: NCT01270984
Drug: Luckyvec 400mg film coated tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: •400mg/tablet, PO, 1 tablet once daily for Period I \& II D1(crossover)
Trial: NCT01270984
Drug: Glivec 100mg film coated tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: •100mg/tablet, PO, 4 tablets once daily for Period I \& II D1(crossover)